The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
Open accessAbstract
Histone deacetylase (HDAC) inhibitors are powerful epigenetic regulators that have enormous therapeutic potential and have pleiotropic effects at the cellular and systemic levels. To date, HDAC inhibitors are used clinically for a wide variety of disorders ranging from hematopoietic malignancies to psychiatric disorders, are known to have anti-inflammatory properties, and are in clinical trials for several other diseases. In addition to influencing gene expression, HDAC enzymes also function as part of large, multisubunit complexes which have many nonhistone targets, alter signaling at the cellular and systemic levels, and result in divergent and cell-type specific effects. Thus, the effects of HDAC inhibitor treatment are too intricate to completely understand with current knowledge but the ability of HDAC inhibitors to modulate the immune system presents intriguing therapeutic possibilities. This review will explore the complexity of HDAC inhibitor treatment at the cellular and systemic levels and suggest strategies for effective use of HDAC inhibitors in biomedical research, focusing on the ability of HDAC inhibitors to modulate the immune system. The possibility of combining the documented anticancer effects and newly emerging immunomodulatory effects of HDAC inhibitors represents a promising new combinatorial therapeutic approach for HDAC inhibitor treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Balliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31
RetractedLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Kadoch, C., Hargreaves, D. C., Hodges, C., Elias, L., Ho, L., Ranish, J., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,458
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
The growing landscape of lysine acetylation links metabolism and cell signalling
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324
Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation
Chen, L.-F., Fischle, W., Verdin, E., & Greene, W. C. (2001) · Science · doi:10.1126/science.1062374 · Cited by 1,222
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
(2002) · PubMed · Cited by 732
Ashburner, B. P., Westerheide, S. D., & Baldwin, A. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.7065-7077.2001 · Cited by 730
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
Zhang, X., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J., Olashaw, N., Parsons, J. T., Yang, X.-J., Dent, S. R., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.033 · Cited by 722
Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation
Jeong, J.-W., Bae, M.-K., Ahn, M.-Y., Kim, S.-H., Sohn, T.-K., Bae, M.-H., Yoo, M.-A., Song, E. J., Lee, K.-J., & Kim, K.-W. (2002) · Cell · doi:10.1016/s0092-8674(02)01085-1 · Cited by 716
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694
Regulation of E2F1 activity by acetylation
Martínez-Balbás, M. A., Bauer, U.-M., Nielsen, S. J., Brehm, A., & Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.662 · Cited by 671
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R.-S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Yu, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.333 · Cited by 583
MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570
Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossati, G., Sozzani, S., Azam, T., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052702999 · Cited by 508
Sirtuins: critical regulators at the crossroads between cancer and aging
Saunders, L. R., & Verdin, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210616 · Cited by 489
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology · doi:10.1038/ni.1673 · Cited by 455
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
Vigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
Histone deacetylases and cancer
Barneda-Zahonero, B., & Parra, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.003 · Cited by 446
Epigenetic regulation of microRNA expression in colorectal cancer
Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman‐Gomez, J., Prosper, F., & Garcia‐Foncillas, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24638 · Cited by 439
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo
Luo, J., Li, M., Tang, Y., Laszkowska, M., Roeder, R. G., & Gu, W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308762101 · Cited by 422
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse
Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P., & Gilkeson, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16153 · Cited by 408
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer
Noonan, E. J., Place, R. F., Pookot, D., Basak, S., Whitson, J. M., Hirata, H., Giardina, C., & Dahiya, R. (2009) · Oncogene · doi:10.1038/onc.2009.19 · Cited by 396
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100800200 · Cited by 366
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358
von Burstin, J., Eser, S., Paul, M. C., Seidler, B., Brandl, M., Messer, M., von Werder, A., Schmidt, A., Mages, J., Pagel, P., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.004 · Cited by 356
Acetylation of MyoD Directed by PCAF Is Necessary for the Execution of the Muscle Program
Sartorelli, V., Puri, P. L., Hamamori, Y., Ogryzko, V., Chung, G., Nakatani, Y., Wang, J. Y. J., & Kedes, L. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80383-4 · Cited by 356
The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60
Patel, J. H., Du, Y., Ard, P. G., Phillips, C., Carella, B., Chen, C.-J., Rakowski, C., Chatterjee, C., Lieberman, P. M., Lane, W. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10826-10834.2004 · Cited by 354
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Zhang, W., & Bieker, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9855 · Cited by 342
Leoni, F., Fossati, G., Lewis, E. C., Lee, J.-K., Porro, G., Pagani, P., Modena, D., Moras, M. L., Pozzi, P., Reznikov, L. L., et al. (2005) · Molecular Medicine · doi:10.2119/2006-00005.dinarello · Cited by 337
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
The Dual Role of Sirtuins in Cancer
Bosch-Presegue, L., & Vaquero, A. (2011) · Genes & Cancer · doi:10.1177/1947601911417862 · Cited by 329
Wang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275
Camelo, S., Iglesias, A. H., Hwang, D., Due, B., Ryu, H., Smith, K., Gray, S. G., Imitola, J., Duran, G., Assaf, B., et al. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.02.022 · Cited by 275
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
Regulation of p53 responses by post-translational modifications
Xu, Y. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401182 · Cited by 265
Salghetti, S. E., Muratani, M., Wijnen, H., Futcher, B., & Tansey, W. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3118 · Cited by 261
Skov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259
Chung, Y.-L., Lee, M.-Y., Wang, A.-J., & Yao, L.-F. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00235-1 · Cited by 253
E2F Family Members Are Differentially Regulated by Reversible Acetylation
Marzio, G., Wagener, C., Gutierrez, M. I., Cartwright, P., Helin, K., & Giacca, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10887 · Cited by 231
Kawai, H., Li, H., Avraham, S., Jiang, S., & Avraham, H. K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11403 · Cited by 226
Invasion and metastasis in pancreatic cancer.
Keleg, S., Büchler, P., Ludwig, R., Büchler, M. W., & Frieß, H. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-14 · Cited by 222
HDAC inhibitors as anti‐inflammatory agents
Adcock, I. M. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707166 · Cited by 216
Nishida, K., Komiyama, T., Miyazawa, S., Shen, Z., Furumatsu, T., Doi, H., Yoshida, A., Yamana, J., Yamamura, M., Ninomiya, Y., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20709 · Cited by 216
Jin, Y.-H., Jeon, E.-J., Li, Q.-L., Lee, Y. H., Choi, J.-K., Kim, W.-J., Lee, K.-Y., & Bae, S.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313120200 · Cited by 211
Aslibekyan, S., Demerath, E. W., Mendelson, M., Zhi, D., Guan, W., Liang, L., Sha, J., Pankow, J. S., Liu, C., Irvin, M. R., et al. (2015) · Obesity · doi:10.1002/oby.21111 · Cited by 210
Li, X.-N., Shu, Q., Su, J. M.-F., Perlaky, L., Blaney, S. M., & Lau, C. C. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0184 · Cited by 201
Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197
Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., & Sanders, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22751 · Cited by 192
HDAC inhibitor–dependent transcriptome and memory reinstatement in cognitive decline models
Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A., Jain, G., Capece, V., Burkhardt, S., Navarro-Sala, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79942 · Cited by 190
Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
Setiadi, A. F., Omilusik, K., David, M. D., Seipp, R. P., Hartikainen, J., Gopaul, R., Choi, K. B., & Jefferies, W. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5270 · Cited by 184
Zhang, W., Kadam, S., Emerson, B. M., & Bieker, J. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.7.2413-2422.2001 · Cited by 182
Mishra, N., Brown, D. R., Olorenshaw, I. M., & Kammer, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051507098 · Cited by 178
Diederichs, S., & Haber, D. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0537 · Cited by 176
HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization
Li, Y., Zhang, X., Polakiewicz, R. D., Yao, T.-P., & Comb, M. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c700185200 · Cited by 173
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors
Slingerland, M., Guchelaar, H.-J., & Gelderblom, H. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000040 · Cited by 161
Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer
Dinarello, C. A., Fossati, G., & Mascagni, P. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00116 · Cited by 159
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 159
Kwon, H.-S., Lim, H. W., Wu, J., Schnölzer, M., Verdin, E., & Ott, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100903 · Cited by 159
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy
Glaros, S., Cirrincione, G. M., Muchardt, C., Kleer, C. G., Michael, C., & Reisman, D. (2007) · Oncogene · doi:10.1038/sj.onc.1210514 · Cited by 150
Qiu, T., Zhou, L. Q., Zhu, W., Wang, T., Wang, J., Shu, Y., & Liu, P. (2013) · Future Oncology · doi:10.2217/fon.12.173 · Cited by 150
Komatsu, Y., Tomizaki, K., Tsukamoto, M., Kato, T., Nishino, N., Sato, S., Yamori, T., Tsuruo, T., Furumai, R., Yoshida, M., et al. (2001) · PubMed · Cited by 145
Woan, K. V., Lienlaf, M., Perez-Villarroel, P., Lee, C., Cheng, F., Knox, T. J., Woods, D. M., Barrios, K., Powers, J. J., Sahakian, E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.002 · Cited by 141
Cheng, F., Lienlaf, M., Perez-Villarroel, P., Wang, H.-W., Lee, C., Woan, K., Woods, D., Knox, T., Bergman, J., Pinilla-Ibarz, J., et al. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.02.019 · Cited by 140
Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells
Larsen, L. H., Tonnesen, M., Rønn, S. G., Størling, J., Jørgensen, S. W., Mascagni, P., Dinarello, C. A., Billestrup, N., & Mandrup-Poulsen, T. R. (2007) · Diabetologia · doi:10.1007/s00125-006-0562-3 · Cited by 132
CREB-binding Protein/p300 Activates MyoD by Acetylation
Polesskaya, A., Duquet, A., Naguibneva, I., Weise, C., Vervisch, A., Bengal, E., Hucho, F., Robin, P., & Harel‐Bellan, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003815200 · Cited by 131
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
Santoro, F., Botrugno, O. A., Zuffo, R. D., Pallavicini, I., Matthews, G. M., Cluse, L. A., Barozzi, I., Senese, S., Fornasari, L., Moretti, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461988 · Cited by 125
Liu, H., Hu, Q., D'Ercole, A. J., & Ye, P. (2009) · Glia · doi:10.1002/glia.20729 · Cited by 121
Acetylation of GATA‐3 affects T‐cell survival and homing to secondary lymphoid organs
Yamagata, T., Mitani, K., Oda, H., Suzuki, T., Honda, H., Asai, T., Maki, K., Nakamoto, T., & Hirai, H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4676 · Cited by 121
Jia, H., Morris, C. D., Williams, R. M., Loring, J. F., & Thomas, E. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415195112 · Cited by 120
Li, F., Wu, R., Cui, X., Zha, L., Yu, L., Shi, H., & Xue, B. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677930 · Cited by 120
Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src
Longworth, M. S., & Laimins, L. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209473 · Cited by 115
Waby, J. S., Chirakkal, H., Yu, D. C. W., Griffiths, G. J., Benson, R., Bingle, C. D., & Corfe, B. M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-275 · Cited by 115
Bridle, B. W., Chen, L., Lemay, C. G., Diallo, J., Pol, J. G., Nguyen, A., Capretta, A. A., He, R., Bramson, J. L., Bell, J. C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.265 · Cited by 110
Huang, P.-H., Chen, C.-H., Chou, C.-C., Sargeant, A. M., Kulp, S. K., Teng, C., Byrd, J. C., & Chen, C. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067702 · Cited by 110
Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts
Sanders, Y. Y., Tollefsbol, T. O., Varisco, B. M., & Hagood, J. S. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0154oc · Cited by 107
Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302778 · Cited by 106
Yamamichi, N., Yamamichi-Nishina, M., Mizutani, T., Watanabe, H., Minoguchi, S., Kobayashi, N., Kimura, S., Ito, T., Yahagi, N., Ichinose, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208716 · Cited by 105
Functional regulation of GATA-2 by acetylation
Hayakawa, F., Towatari, M., Ozawa, Y., Tomita, A., Privalsky, M. L., & Saito, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603389 · Cited by 103
A non-isotopic assay for histone deacetylase activity
Hoffmann, K., Jung, M., Brosch, G., & Loidl, P. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.9.2057 · Cited by 102
Woods, D. M., Woan, K. V., Cheng, F., Wang, H., Perez-Villarroel, P., Lee, C., Lienlaf, M., Atadja, P. W., Seto, E., Weber, J. S., et al. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e328364c0ed · Cited by 101
Lee, J. Y., Maeng, S., Kang, S. R., Choi, H. Y., Oh, T. H., Ju, B. G., & Yune, T. Y. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2013.3146 · Cited by 100
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer
Bae, H. J., Jung, K. H., Eun, J. W., Shen, Q., Kim, H. S., Park, S. J., Shin, W. C., Yang, H. D., Park, W. S., Lee, J. Y., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.019 · Cited by 99
LaBonte, M. J., Wilson, P. M., Fazzone, W., Groshen, S., Lenz, H.-J., & Ladner, R. D. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-67 · Cited by 99
Epigenetics and depression: current challenges and new therapeutic options
Schroeder, M., Krebs, M., Bleich, S., & Frieling, H. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833d16c1 · Cited by 97
Cho, J.-H., Dimri, M., & Dimri, G. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624361 · Cited by 88
Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Shuttleworth, S. J., Bailey, S. G., & Townsend, P. A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011430 · Cited by 88
Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8
Wada, T., Kikuchi, J., & Furukawa, Y. (2012) · EMBO Reports · doi:10.1038/embor.2011.247 · Cited by 87
Drogaris, P., Villeneuve, V., Pomiès, C., Lee, E. H., Bourdeau, V., Bonneil, É., Ferbeyre, G., Verreault, A., & Thibault, P. (2012) · Scientific Reports · doi:10.1038/srep00220 · Cited by 87
Manning, J. E., Indrová, M., Lubyová, B., Přibylová, H., Bieblová, J., Hejnar, J., Šímová, J., Jandlová, T., Bubenik, J., & Reiniš, M. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02689.x · Cited by 87
Wu, X., Yi, T., Hou, J., Meng, X., & Shi, J. (2012) · Neoplasia · doi:10.1593/neo.121236 · Cited by 85
Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis
Cantley, M. D., Fairlie, D. P., Bartold, P. M., Marino, V., Gupta, P. K., & Haynes, D. R. (2015) · Rheumatology · doi:10.1093/rheumatology/kev022 · Cited by 84
Lin, K., Wang, Y., Chen, C., Ho, C., Su, W.-H., & Jou, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0633 · Cited by 83
The Therapeutic Potential of HDAC Inhibitors in the Treatment of Multiple Sclerosis
Faraco, G., Cavone, L., & Chiarugi, A. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00077 · Cited by 80
HDAC inhibitor therapy in autoimmunity and transplantation
Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y., & Wang, L. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200593 · Cited by 78
Romidepsin targets multiple survival signaling pathways in malignant T cells
Valdez, B. C., Brammer, J. E., Li, Y., Murray, D. L., Liu, Y., Hosing, C. M., Nieto, Y. L., Champlin, R. E., & Andersson, B. S. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.83 · Cited by 75
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Robert, L., Ribas, A., & Hu‐Lieskovan, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.001 · Cited by 73
Sato, N., Ohta, T., Kitagawa, H., Kayahara, M., Ninomiya, I., Fushida, S., Fujimura, T., Nishimura, G., Shimizu, K., & Miwa, K. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.3.679 · Cited by 71
Histone Deacetylase Inhibitors as Immunomodulators in Cancer Therapeutics
Shen, L., Orillion, A. R., & Пили, Р. (2016) · Epigenomics · doi:10.2217/epi.15.118 · Cited by 66
Deacetylase inhibitors - focus on non-histone targets and effects
Ocker, M. (2010) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v1.i5.55 · Cited by 60
Zhai, Y., Chen, X. X., Yu, D., Li, T., Cui, J., Wang, G., Hu, J., & Li, W. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.003 · Cited by 56
Andresen, L. O., Jensen, H., Pedersen, M. T., Hansen, K. A., & Skov, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.12.8235 · Cited by 55
Saijo, K., Katoh, T., Shimodaira, H., Oda, A., Takahashi, O., & Ishioka, C. (2012) · Cancer Science · doi:10.1111/cas.12002 · Cited by 55
Schoepflin, Z. R., Shapiro, I. M., & Risbud, M. V. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2787 · Cited by 53
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies
Adams, C. M., Hiebert, S. W., & Eischen, C. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1751 · Cited by 53
Halsall, J. A., Turan, N., Wiersma, M., & Turner, B. M. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0021-9 · Cited by 50
Nakane, K., Fujita, Y., Terazawa, R., Atsumi, Y., Kato, T., Nozawa, Y., Deguchi, T., & Ito, M. (2011) · International Journal of Urology · doi:10.1111/j.1442-2042.2011.02888.x · Cited by 46
Ciossek, T., Julius, H., Wieland, H., Maier, T. M., & Beckers, T. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.07.024 · Cited by 45
Sanda, T., Okamoto, T., Uchida, Y., Nakagawa, H., Iida, S., Kayukawa, S., Suzuki, T., Oshizawa, T., Suzuki, T., Miyata, N., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404902 · Cited by 43
Acetylation of MyoD by p300 Requires More Than Its Histone Acetyltransferase Domain
Polesskaya, A., & Harel‐Bellan, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106501200 · Cited by 43
10.2119/Molecular Medicine-2004-00038
Wade, R. H. (2000) · Applied Physics Letters · doi:10.2119/molecular · Cited by 43
Salghetti, S. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050007597 · Cited by 42
Saijo, K., Imamura, J., Narita, K., Oda, A., Shimodaira, H., Katoh, T., & Ishioka, C. (2014) · Cancer Science · doi:10.1111/cas.12585 · Cited by 41
Recent progress in the development of assays suited for histone deacetylase inhibitor screening
Wegener, D., Hildmann, C., & Schwienhorst, A. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.008 · Cited by 41
Liddo, R. D., Valente, S., Taurone, S., Zwergel, C., Marrocco, B., Turchetta, R., Conconi, M. T., Scarpa, C., Bertalot, T., Schrenk, S., et al. (2016) · Autoimmunity · doi:10.3109/08916934.2015.1134510 · Cited by 31
Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer
Riester, D., Hildmann, C., Schwienhorst, A., & Meyer‐Almes, F. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2006.12.019 · Cited by 29
Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases
Edwards, A. J. P., & Pender, S. L. F. (2011) · Biochemical Society Transactions · doi:10.1042/bst0391092 · Cited by 29
Soriano‐Cantón, R., Pérez‐Villalba, A., Morante‐Redolat, J. M., Marqués‐Torrejón, M. Á., Pallàs, M., Pérez‐Sánchez, F., & Fariñas, I. (2015) · Aging Cell · doi:10.1111/acel.12328 · Cited by 26
Sewal, A. S., Patzke, H., Perez, E., Park, P., Lehrmann, E., Zhang, Y., Becker, K. G., Fletcher, B. R., Long, J. M., & Rapp, P. R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4339-14.2015 · Cited by 24
Darvishi, M., Tiraihi, T., Mesbah‐Namin, S. A., Delshad, A. A., & Taheri, T. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1429-5 · Cited by 23
A Substrate-Independent TR-FRET Histone Deacetylase Inhibitor Assay
Marks, B. D., Fakhoury, S. A., Frazee, W. J., Eliason, H. C., & Riddle, S. M. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111422102 · Cited by 23
Ni, M., Esposito, E., Raj, V. P., Muzi, L., Zunino, F., Zuco, V., Cominetti, D., Penco, S., & Pozzo, A. D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.10.004 · Cited by 22
Soriano, F. X., Chawla, S., Skehel, P., & Hardingham, G. E. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12058 · Cited by 11
Cited by
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Vizioli, M. G., Liu, T., Miller, K. N., Robertson, N. A., Gilroy, K., Lagnado, A. B., Perez-Garcia, A., Kiourtis, C., Dasgupta, N., Lei, X., et al. (2020) · Genes & Development · doi:10.1101/gad.331272.119 · Cited by 359
Epigenetics and Trained Immunity
van der Heijden, C. D. C. C., Noz, M. P., Joosten, L. A. B., Netea, M. G., Riksen, N. P., & Keating, S. T. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7310 · Cited by 278
Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019) · Oncogene · doi:10.1038/s41388-019-0897-0 · Cited by 121
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
Metadata
- Authors
- Hull, E. E., Montgomery, M. R., & Leyva, K. J.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-15
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2475853404
- Cited by
- 313
- References
- 140
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.